[en] We hypothesized that the active targeting of αvβ3 integrin overexpressed in neoangiogenic blood vessels and glioblastoma (GBM) cells combined with magnetic targeting of paclitaxel- and SPIO-loaded PLGA-based nanoparticles could improve accumulation of nanoparticles in the tumor and therefore improve the treatment of GBM. Methods: PTX/SPIO PLGA nanoparticles with or without RGD-grafting were characterized. Their in vitro cellular uptake and cytotoxicity was evaluated by fluorospectroscopy and MTT assay. In vivo safety and anti-tumor efficacy of different targeting strategies was evaluated in orthotopic U87MG tumor model over multiple intravenous injections. Results: The nanoparticles of 250nm were negatively charged. RGD targeted nanoparticles showed a specific and higher cellular uptake than untargeted nanoparticles by activated U87MG and HUVEC cells. In vitro IC50 of PTX after 48h was approximately 1 ng/mL for all the PTX-loaded nanoparticles. The median survival time of the mice treated with magnetic targeted nanoparticles was higher than the control (saline) mice or mice treated with other evaluated strategies. The 6 doses of PTX did not induce any detectable toxic effects on liver, kidney and heart when compared to Taxol. Conclusion. The magnetic targeting strategy resulted in better therapeutic effect than the other targeting strategies (passive, active).
Research Center/Unit :
CESAM - Complex and Entangled Systems from Atoms to Materials - ULiège Center for Education and Research on Macromolecules (CERM)
Disciplines :
Materials science & engineering Chemistry
Author, co-author :
Ganipineni, Lakshmi Pallavi; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials
Ucakar, Bernard; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials
Joudiou, Nicolas; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Nuclear and Electron Spin Technologies Platform (NEST)
Riva, Raphaël ; University of Liège (ULiège), Complex and Entangled Systems from Atoms to Materials (CESAM), Center for Education and Research on Macromolecules (CERM)
Jérôme, Christine ; University of Liège (ULiège), Complex and Entangled Systems from Atoms to Materials (CESAM), Center for Education and Research on Macromolecules (CERM)
Gallez, Bernard; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Nuclear and Electron Spin Technologies Platform (NEST)
Danhier, Fabienne; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials
Préat, Véronique; Université catholique de Louvain (UCL), Brussels, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials
Language :
English
Title :
Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma
Publication date :
2019
Journal title :
Journal of Drug Targeting
ISSN :
1061-186X
eISSN :
1029-2330
Publisher :
Taylor & Francis, United Kingdom
Volume :
27
Issue :
5-6
Pages :
614-623
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique Télévie Fondation contre le Cancer
Stupp R, Taillibert S, Kanner AA. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–2543.
Ganipineni LP, Danhier F, Préat V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release. 2018;281:42–57.
Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Front Physiol. 2018;9:170.
Kang T, Zhu Q, Jiang D, et al. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment. Biomaterials. 2016;101:60–75.
Cho J-H, Kim AR, Kim S-H, et al. Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. Acta Biomater. 2017;47:182–192.
Jiang Y, Wang X, Liu X, et al. Enhanced antiglioma efficacy of ultrahigh loading capacity paclitaxel prodrug conjugate self-assembled targeted nanoparticles. ACS Appl Mater Interfaces. 2017;9:211–217.
Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–522.
Strohbehn G, Coman D, Han L, et al. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. J Neurooncol. 2015;121:441–449.
Arshad A, Yang B, Bienemann AS, et al. Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma. PLoS One. 2015;10:e0132266.
Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–2681.
Wang B, Lv L, Wang Z, et al. Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel. Sci Rep. 2015;5:16589.
Liu Y, Ran R, Chen J, et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials. 2014;35:4835–4847.
Jiang X, Sha X, Xin H, et al. Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials. 2013;34:2969–2979.
Ganipineni LP, Ucakar B, Joudiou N, et al. Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma. Ijn. 2018;13:4509–4521.
Zhou J, Atsina K-B, Himes BT, et al. Novel delivery strategies for glioblastoma. Cancer J. 2012;18:89–99.
Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135–146.
Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108–121.
Franovic A, Elliott KC, Seguin L, et al. Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence. Cancer Res. 2015;75:4466–4473.
Ye Y, Xu B, Nikiforovich GV, et al. Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging. Bioorg Med Chem Lett. 2011;21:2116–2120.
Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–2973.
Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin on Drug Deliv. 2009;6:53–70.
Chertok B, Moffat BA, David AE, et al. iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29:487–496.
Fontes de Paula Aguiar M, Bustamante Mamani J, Klei Felix T, et al. Magnetic targeting with superparamagnetic iron oxide nanoparticles for in vivo glioma. Nanotechnol Rev. 2017;6:449–472.
Lee C, Kim GR, Yoon J, et al. In vivo delineation of glioblastoma by targeting tumor-associated macrophages with near-infrared fluorescent silica coated iron oxide nanoparticles in orthotopic xenografts for surgical guidance. Sci Rep. 2018;8:11122.
Wankhede M, Bouras A, Kaluzova M, et al. Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol. 2012;5:173–186.
Schleich N, Po C, Jacobs D, et al. Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. J Control Release. 2014;194:82–91.
Pourcelle V, Freichels H, Stoffelbach F, et al. Light induced functionalization of PCL-PEG block copolymers for the covalent immobilization of biomolecules. Biomacromolecules. 2009;10:966–974.
Freichels H, Danhier F, Préat V, et al. Fluorescent labeling of degradable poly(lactide-co-glycolide) for cellular nanoparticles tracking in living cells. Int J Artif Organs. 2011;34:152–160.
Garinot M, Fiévez V, Pourcelle V, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release. 2007;120:195–204.
Pourcelle V, Devouge S, Garinot M, et al. PCL − PEG-based nanoparticles grafted with GRGDS peptide: preparation and surface analysis by XPS. Biomacromolecules. 2007;8:3977–3983.
Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17:1247–1248.
Schleich N, Sibret P, Danhier P, et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharm. 2013;447:94–101.
Chang M-W, Lo J-M, Juan H-F, et al. Combination of RGD compound and low-dose paclitaxel induces apoptosis in human glioblastoma cells. PLoS One. 2012;7:e37935.
Danhier F, Vroman B, Lecouturier N, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release. 2009;140:166–173.
Bastiancich C, Vanvarenberg K, Ucakar B, et al. Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J Control Release. 2016;225:283–293.
Cui Y, Zhang M, Zeng F, et al. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces. 2016;8:32159–32169.
Gu G, Hu Q, Feng X, et al. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Biomaterials. 2014;35:8215–8226.
Kang W, Svirskis D, Sarojini V, et al. Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: an in vitro boron neutron capture therapy study. Oncotarget. 2017;8:36614–36627.
Inda M-d-M, Bonavia R, Seoane J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 2014;6:226–239.
Bhattacharjee S. DLS and zeta potential–What they are and what they are not? J Control Release. 2016;235:337–351.
Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284.
Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
Rosenblum D, Joshi N, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.
Schnell O, Krebs B, Wagner E, et al. Expression of Integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18:378–386.
Hou C-H, Yang R-S, Hou S-M, et al. TNF-α increases αvβ3 integrin expression and migration in human chondrosarcoma cells. J Cell Physiol. 2011;226:792–799.
Brüning A, Runnebaum IB. CAR is a cell–cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFα, and TGFβ. Gene Ther. 2003;10:198.
Wang F, Li Y, Shen Y, et al. The functions and applications of RGD in tumor therapy and tissue engineering. Int J Mol Sci. 2013;14:13447–13462.
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951.
